Drugs for Neglected Diseases initiative (DNDi)
Sessions, Events, and Presentations

Visit us at Booth #5!
Royal Tulip Hotel
Rua Aquarela do Brasil, n° 75 - São Conrado - 22610-010
Rio de Janeiro, Brazil

MONDAY, SEPTEMBER 24

07:30-8:40: CLOSED SESSION: The use of ASMQ in Brazil: *P. falciparum* decline in the artemisinin resistance contention scenario
Room: Âmbar

09:00-11:00: Advances in Cutaneous Leishmaniasis Treatment (Round Table; Sanofi)
Room: Ágata
Chairs: Ana Rabello (Brazil); Robert Sebbag (France)
Speakers:
- *Global epidemiology of cutaneous leishmaniasis*: Jorge Alvar (WHO)
- *Unmet patient needs: new topical treatments in development*: Ana Rabello (Brazil)
- *Paromomycin gentamycin combination*: Max Grogl (USA)
- *Amphotericin B*: Ivan Velez (Colombia)
- *Meglumine antimoniate*: Benedict Blayney (France)
- *Challenges in the design of cutaneous leishmaniasis trials*: Byron Arana, DNDi (Switzerland) (replacing Farrokh Modabber)

14:00-15:30: Neglected Disease R&D Financing and Framework (MSF session)
Room: Ágata
Chair: Michelle Childs, Médecins Sans Frontières (MSF) Access Campaign (Switzerland)
Speakers:
- Julien Potet, MSF Access Campaign (France)
- Gabriela Chaves, DNDi Latin America (Brazil)
19:00-19:30: CLOSED SESSION: Cocktail Reception: Product Development Partnerships (PDPs) for Neglected Diseases
Co-hosted by the Medicines for Malaria Venture (MMV) and DNDi
Room: Ágata

Medicines for Malaria Venture (MMV) and Drugs for Neglected Diseases initiative (DNDi) invite you to the session

PRODUCT DEVELOPMENT PARTNERSHIPS (PDPs) FOR NEGLECTED DISEASES

Since the last decade, PDPs have helped to create the largest pipeline of new technologies to treat, prevent and diagnose poverty-related and neglected diseases in developing countries. In the last 12 years, DNDi has delivered 2 new treatments in Latin America and MMV has delivered 4 new antimalarials.

In South America, millions of people are at risk of poverty-related and tropical diseases such as Malaria, Leishmaniasis and Chagas disease.

Join us in this event and learn more about PDPs, our missions and work in the region!
TUESDAY, SEPTEMBER 25

09:00-11:00: Progressing New Chemical Entities (NCEs) Through Clinical Development for the Treatment of Neglected Tropical Diseases (Round Table: DNDi session)
Room: Ametista/Safira/Rubi

Chair: Ana Rabello, Oswaldo Cruz Foundation/FIOCRUZ (Brazil)
Co-Chair: Silvia Gold, Mundo Sano Foundation (Argentina)

Speakers:
- **High throughput screening and hit prioritization strategies for leishmaniasis and Chagas disease**: Carolina Borsoi Moraes, Chagas Team Coordinator, Center for Neglected Diseases Drug Discovery Institut Pasteur Korea
- **SCYX-7158: an oxaborole entering Phase I for the treatment of HAT (sleeping sickness)**: Antoine Tarral, Head of HAT Clinical Program, DNDi
- **E1224 for Chagas disease: news on a drug candidate from a promising class**: Isabela Ribeiro, Head of Chagas Clinical Program, DNDi; Frederick Duncanson, Eisai (TBC)
- **Nitroimidazoles as a potential new series for visceral leishmaniasis: fexinidazole and VL-2098**: Shyam Sundar, Professor of Medicine, Institute of Medical Sciences Banaras Hindu University (BHU), Varanasi, India

16:45-18:45: Developing Safe and Efficacious Drugs to Treat Chagas Disease (Round Table: DNDi session)
Room: Gavea B

Chair: Isabela Ribeiro, Head of Chagas Clinical Program, DNDi (Brazil)
Co-Chair: Alejandro Schijman, CONICET (Argentina)

Speakers:
- **Early medicinal chemistry to identify new candidate drugs**: Martine Keenan, Head of Drug Discovery, Epichem, Australia
- **Potential drug candidate series: nitroimidazoles and fenarimols**: Eric Chatelain, Head of Chagas Discovery & Preclinical Program, DNDi (Switzerland)
- **Efficacy, safety and population pharmacokinetics of benznidazole in children: presentation of results**: Jaime Altcheh, Head of Parasitology, Ricardo Gutiérrez Children’s Hospital (Argentina)
- **Biomarkers of therapeutic response in Chagas disease: recent advances and future perspectives**: NHEPACHA, Joaquim Gascón, CRESIB (Spain)
- **Optimization of sampling procedure for PCR technique to assess parasitological response for patients with chronic Chagas disease treated with benznidazole in Aiquile, Bolivia: preliminary results**: Laurence Flevaud, Laboratory Advisor, MSF (Spain)
WEDNESDAY, SEPTEMBER 26

09:00-12:30: Fighting Neglect: Finding Ways to Manage and Control Visceral Leishmaniasis, Human African Trypanosomiasis and Chagas Disease (Workshop: MSF session)
Room: Ágata

Chair: Gemma Ortiz, MSF-Spain

Speakers:
- Nines Lima, MSF-Spain
- Laurence Flevaud, MSF-Spain
- Koert Ritmeijer, MSF-Holland
- Rachel ter Horst, MSF-Holland
- François Chappuis, Geneva University Hospitals (Switzerland)
- Carolina Batista, MSF-Brazil
- Lucia Brum, MSF-Brazil
- Henry Rodriguez, MSF-Paraguay
- Julien Potet, Access Campaign, MSF-France
- Eric Stobbaerts, DNDi Latin America (Brazil)

Topics:
- Setting the scene on the kinetoplastids
- Challenges and advances in diagnosing tri-tryps
- Treatment is possible: but what else is needed?
- Disease control: HAT, Chagas disease and visceral leishmaniasis
- Panel discussion

14:00-15:30: Protozoan: African Trypanosomiasis (Workshop)
Room: Jade

Coordinators: Philippe Buscher (Belgium); Stijn Deborggraeve (Belgium)

Presentations:
- Deep annotation of Trypanosoma brucei endogenous siRNAs yields insights into their sources, variation and functions in two life stages of the parasite: Ling-Ling Zhenga, Yan-Zi Wenb, Jian-Hua Yanga, Jian-You Liaoa, Peng Shaoa, Hui Xua, Hui Zhoua, Zhao-Rong Lunaa, Francisco J. Ayalac, Liang-Hua Qua
- Immunotherapeutic efficacy of DNA vaccines in the experimental model of African trypanosomiasis: De Sousa KP, Pestana S, Teixeira AF, Atouguia J, Silva MS
- Dose regimen assessment for oral fexinidazole: Virginie Gualano, Mathieu Felices, Eric Evene, Séverine Blesson, Antoine Tarral
• **Effect of food on the pharmacokinetic of single dose of fexinidazole in healthy male volunteers of sub-Saharan African origin:** Antoine Tarral, Séverine Blesson, Olaf Valverde, Virginie Gualano, Mathieu Felices, Lionel Hovsepian, Eric Evene, Nathalie Strub-Wourgaft

• **Multiple dose safety and pharmacokinetics study of fexinidazole dosed under fasting conditions in health male volunteers of sub-Saharan African origin:** Olaf Valverde, Antoine Tarral, Séverine Blesson, Virginie Gualano, Mathieu Felices, Lionel Hovsepian, Eric Evene, Pascal Voiriot, Nathalie Strub-Wourgaft

16:45-18:45: Treatment of Leishmaniasis: Current Situation and Needs for New Drugs (Round Table)
Room: Gavea B

Chairs: Reynaldo Dietze (Brazil); Shyam Sundar (India)

Speakers:
• **Use of miltefosine for treatment of cutaneous leishmaniasis:** Ivan Velez (Colombia)
• **Best treatment for visceral leishmaniasis in HIV-infected patients:** Koert Ritmeijer, MSF (Netherlands)
• **Treatment of kala azar: the great Indian experience:** Shyam Sundar (India)
• **Inhibiting apoptotic mimicry as a potential adjuvant treatment in leishmanial infection:** Marcello Andre Barcinski (Brazil)

THURSDAY, SEPTEMBER 27

9:00-12:00: Use of Treatment as Prevention for Malaria: Exploring Innovative Strategies (MSF session)
Room: Ágata

Chair: Isabela Ribeiro, DNDi, Brazil

Speakers:
• Intermittent preventive treatment: Francois Nosten, SMRU
• Preventive treatment in epidemic situation: Esther Sterck, MSF
• Use of primaquine to decrease transmission: Chris Drakeley, LSHTM Malaria Centre
• **ASMQ post-treatment effect:** Isabela Ribeiro, DNDi
OTHER INFORMATION

Conference website: http://ictmm2012.ioc.fiocruz.br
Conference online program: http://ictmm2012.ioc.fiocruz.br/program.html

DNDi website: www.dndi.org
DNDi Latin America website (Português, Español): www.dndi.org.br

Media Contacts (on site):
Mariana Abdalla (Português, Español, English)
Communications Assistant
DNDi Latin America
e-mail: mabdalla@dndi.org.br
Mobile: +55 (21) 8108 2466

Oliver Yun (English)
Communications Manager
DNDi North America
e-mail: oyun@dndi.org
Mobile: +1-646-266-5216

Follow us!
Facebook: facebook.com/dndi.org
Twitter: twitter.com/DNDi_HQ
YouTube: youtube.com/dndi2003

Drugs for Neglected Diseases initiative, Latin America ▪ Rua Santa Heloísa, 5, Jd. Botânico. 22460-080 ▪ Rio de Janeiro, Brasil
Tel: +55 (21) 2215 2941 ▪ Email: info@dndi.org.br ▪ Web: www.dndi.org.br